Zydus Lifesciences Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®. NUFYMCO®. BLA has been approved by the USFDA".
Press Release Dec 23 2025
Filed with NSE · · 3 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has announced a partnership with Bioeq for the U.S. commercialization rights of NUFYMCO®, a biosimilar to Lucentis®, which has received approval from the USFDA. Under this agreement, Bioeq will handle development and manufacturing, while Zydus will focus on commercialization in the U.S. market. This collaboration aims to enhance access to affordable ophthalmology care for patients in the U.S.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
- Press Release Dec 19 2025
- Press Release Dec 15 2025
- Press Release Dec 10 2025
- Press Release Dec 09 2025
Later from Zydus Lifesciences
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
- Zydus Lifesciences Limited Press Release Jan 13 2026
- Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
- Press Release Jan 15 2026
- Zydus Lifesciences Limited Press Release Jan 22 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences